Treatment of Alzheimer’s Disease with Clioquinol
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
As heavy metal ions may be implicated in the formation of senile plaques in Alzheimer-afflicted brains, treatment with clioquinol was tested in 20 patients with Alzheimer’s disease. Clioquinol is a chelator that crosses the blood-brain barrier and has greater affinity for zinc and copper ions than for calcium and magnesium ions. Treatment was given for 21 days at doses of 20 mg/day to 10 patients and 80 mg/day to another 10 patients. The study was blind to the dosages but included no controls. Cerebrospinal fluid (CSF) investigations revealed a significant increase at day 7 and a decrease at day 21 in Tau protein and growth-associated protein (GAP43). These proteins are increased in Alzheimer’s disease and considered as rather stable markers. The initial increase may indicate a temporary cytotoxicity to the brain and/or an increased release into the CSF from stores in the tissue, possibly from senile plaques where the proteins are accumulated. The levels of CSF-Tau protein correlated positively and significantly with the serum levels of copper and also with the serum copper/zinc ratio. Clinical ratings showed slight improvement after 3 weeks treatment with clioquinol in this open study.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, iron chelators have demonstrated therapeutic benefits in Alzheimer's [1674,1710,1769-1771], Parkinson's [1037,1729,1772], cold-induced brain injury [1773,1774], coronary disease [714,797], renal diseases [1775], various kinds of infection [1763] and of course in iron overload diseases [1762,1767].”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1771]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Rapid induction of Alzheimer A beta amyloid formation by zinc
Bush, A., Pettingell, W., Multhaup, G., d Paradis, M., Vonsattel, J., Gusella, J., Beyreuther, K., Masters, C., & Tanzi, R. (1994) · Science · doi:10.1126/science.8073293 · Cited by 1,522
Atwood, C. S., Moir, R. D., Huang, X., Scarpa, R. C., Bacarra, N. M. E., Romano, D. M., Hartshorn, M. A., Tanzi, R. E., & Bush, A. I. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.12817 · Cited by 1,009
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Self-citationIntramuscular desferrioxamine in patients with Alzheimer's disease
MCLACHLAN, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)92978-b · Cited by 764
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660
Self-citationThe Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy.
Mohs, R. C., Rosen, W. G., & Davis, K. L. (1983) · PubMed · Cited by 425
Primary structure and transcriptional regulation of GAP-43, a protein associated with nerve growth
Basi, G. S., Jacobson, R. D., Virág, I., Schilling, J., & Skene, J. H. P. (1987) · Cell · doi:10.1016/0092-8674(87)90616-7 · Cited by 355
Cited by
Items 101–200 of 222
Clioquinol effects on tissue chelatable zinc in mice
Nitzan, Y. B., Sekler, I., Frederickson, C. J., Coulter, D. A., Balaji, R. V., Liang, S., Margulis, A., Hershfinkel, M., & Silverman, W. F. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0462-7 · Cited by 52
Ancelin, M.-L., Christen, Y., & Ritchie, K. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000102567 · Cited by 50
Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease
de la Monte, S. (2012) · Frontiers in Bioscience · doi:10.2741/482 · Cited by 49
Nanotherapeutics for Alzheimer’s disease (AD): Past, present and future
Fazil, M., Shadab, Baboota, S., Sahni, J. K., & Ali, J. (2011) · Journal of drug targeting · doi:10.3109/1061186x.2011.607499 · Cited by 52
Ubiquitin biology in neurodegenerative disorders: From impairment to therapeutic strategies
Kumar, D., Ambasta, R. K., & Kumar, P. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101078 · Cited by 54
Clioquinol for the treatment of Alzheimer's Disease
Jenagaratnam, L., & McShane, R. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005380.pub2 · Cited by 54
High antitumor activity of 5,7-dihalo-8-quinolinolato tin(IV) complexes
Chen, Z., Peng, Y., Gu, Y., Liu, Y., Liu, M., Huang, K.-B., Hu, K., & Liang, H. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.12.030 · Cited by 48
Gaeta, A., Molina‐Holgado, F., Kong, X. L., Salvage, S., Fakih, S., Francis, P. T., Williams, R. J., & Hider, R. C. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.12.007 · Cited by 49
Glycosylated tetrahydrosalens as multifunctional molecules for Alzheimer's therapy
Storr, T., Scott, L. E., Bowen, M. L., Green, D. E., Thompson, K. H., Schugar, H. J., & Orvig, C. (2009) · Dalton Transactions · doi:10.1039/b902545f · Cited by 45
Desferoxamine reverses neonatal iron-induced recognition memory impairment in rats
de Lima, M. N. M., Presti-Torres, J., Caldana, F., Grazziotin, M. M., Scalco, F. S., Guimarães, M. R., Bromberg, E., Franke, S. I. R., Henriques, J. A. P., & Schröder, N. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.06.002 · Cited by 49
“A few human studies have indicated that iron chelators may slow the clinical progression of the dementia associated with Alzheimer's disease (Crapper et al., 1991; Regland et al., 2001).”
BackgroundNovel therapeutics for Alzheimer's disease: an update.
Bonda, D., Lee, H. P., Lee, H., Friedlich, A. L., Perry, G. L., Zhu, X., & Smith, M. A. (2010) · PubMed · Cited by 48
Cukierman, D. S., Accardo, E., Gomes, R. G., Falco, A. D., Miotto, M., Freitas, M. C. R., Lanznaster, M., Fernández, C. O., & Rey, N. A. (2018) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-018-1606-0 · Cited by 51
Copper-binding compounds as proteasome inhibitors and apoptosis inducers in human cancer
Kenyon, G. D. (2006) · Frontiers in bioscience · doi:10.2741/2054 · Cited by 42
“Recently, interest in CQ has reemerged due to studies involving its use, in combination with B12, for treatment of Alzheimer’s Disease (45, 49, 50).”
BackgroundMetal ion chelation in neurodegenerative disorders
Angel, I., Bar, A., Horovitz, T., Taler, G., Krakovsky, M., Resnitsky, D., Rosenberg, G., Striem, S., Friedman, J. E., & Kozak, A. (2002) · Drug Development Research · doi:10.1002/ddr.10083 · Cited by 42
“The first results from an open clinical study of clioquinol in patients with AD are now available [Regland et al., 2001].”
BackgroundDevelopment of a copper-clioquinol formulation suitable for intravenous use
Wehbe, M., Malhotra, A. K., Anantha, M., Lo, C., Dragowska, W. H., Santos, N. D., & Bally, M. B. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0455-7 · Cited by 43
“the use of CQ in Alzheimer’s suggests that it crosses the blood brain barrier and thus the glioma cell line U251was also tested [5].”
BackgroundChauvin, D., Bell, J., Leray, I., Ledoux-Rak, I. N., & Nguyên, C. T. (2018) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2018.10.053 · Cited by 45
Seo, B.-R., Lee, S.-J., Cho, K. S., Yoon, Y. H., & Koh, J. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.006 · Cited by 45
“Subsequently, several metal- interacting compounds were found effective to varying degrees in reducing Ab burden in mouse models of AD (Cherny et al., 2001; Regland et al., 2001).”
New applications of old metal-binding drugs in the treatment of human cancer
Dou, Q. P. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s274 · Cited by 45
New applications of old metal-binding drugs in the treatment of human cancer
Sara, M. S. (2011) · Frontiers in Bioscience-Scholar · doi:10.2741/274 · Cited by 38
“This discovery led to the initiation of two clinical trials which showed that CQ is beneficial in treating Alzheimer’s disease with no visible toxicity (130-131).”
MethodAspartic Proteases Involved in Alzheimer's Disease
Schmidt, B. (2003) · ChemBioChem · doi:10.1002/cbic.200200532 · Cited by 46
Advances in protein misfolding, amyloidosis and its correlation with human diseases
Kundu, D., Prerna, K., Chaurasia, R., Bharty, M. K., & Dubey, V. K. (2020) · 3 Biotech · doi:10.1007/s13205-020-2166-x · Cited by 43
Tuller, E. R., Brock, A. L., Yu, H., Lou, J. R., Benbrook, D. M., & Ding, W. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.02.002 · Cited by 36
Sparks, D. L. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:24:1:097 · Cited by 37
Maheshwaran, S., Akilarasan, M., Chen, T.-W., Chen, S., Tamilalagan, E., Jiang, T., Alabdullkarem, E. A., & Soylak, M. (2021) · Microchimica Acta · doi:10.1007/s00604-021-04758-5 · Cited by 34
“However, CQ has been widely used in many countries as a therapeutic agent [6].”
BackgroundArbo, B. D., Schimith, L. E., dos Santos, M. G., & Hort, M. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174800 · Cited by 34
Smythe, G. A., Poljak, A., Bustamante, S., Braga, O., Maxwell, A., Grant, R., & Sachdev, P. S. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0135-0_83 · Cited by 33
Vranec, P., Potočňák, I., Sabolová, D., Kuchárová, V., Ipóthová, Z., Pisarčíková, J., & Paulíková, H. (2013) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2013.10.018 · Cited by 32
Frontiers in Alzheimer’s disease therapeutics
Stone, J. G., Casadesús, G., Rothenberg, K. G., Siedlak, S. L., Wang, X., Zhu, X., Perry, G. L., Castellani, R. J., & Smith, M. A. (2010) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310382817 · Cited by 35
“Metal chelators such as ethylenediaminetetracetic acid (EDTA), desferrioxamine, and iodochlorhydroxyquin (clioquinol) [Ritchie et al. 2003; Regland et al. 2001; Crapper McLachlan et al. 1991] can prevent the detrimental interaction between redox metals and Ab [Liu et al. 2006; Opazo et al. 2002;…”
Serum copper in Alzheimer’s disease and vascular dementia
Agarwal, R., Kushwaha, S. S., Tripathi, C. B., Singh, N. K., & Chhillar, N. (2008) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-008-0081-8 · Cited by 34
“In vivo studies done in AD patients show altered peripheral copper metabolism along with raised copper in serum (20-22).”
BackgroundClioquinol independently targets NF-kappaB and lysosome pathways in human cancer cells.
Yu, H., Lou, J. R., & Ding, W. (2010) · PubMed · Cited by 32
ER chaperone–metal interactions: Links to protein folding disorders
Tiffany‐Castiglioni, E., & Qian, Y. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2012.02.007 · Cited by 33
The effects of clioquinol in morphogenesis, cell membrane and ion homeostasis in Candida albicans
You, Z., Zhang, C., & Ran, Y. (2020) · BMC Microbiology · doi:10.1186/s12866-020-01850-3 · Cited by 34
Metal protein attenuating compounds for the treatment of Alzheimer's disease
Sampson, E. L., Jenagaratnam, L., & McShane, R. H. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005380.pub3 · Cited by 31
Jackson, A. C., Liu, J., Vallanat, B., Jones, C. P., Nelms, M., Patlewicz, G. Y., & Corton, J. C. (2020) · Metallomics · doi:10.1039/d0mt00071j · Cited by 30
Transition metal chelator therapy - a potential treatment for Alzheimer's disease?
Gnjec, A., Fonte, J., Atwood, C., & Martins, R. N. (2002) · Frontiers in bioscience · doi:10.2741/gnjec · Cited by 30
Metal protein attenuating compounds for the treatment of Alzheimer's dementia
Sampson, E. L., Jenagaratnam, L., & McShane, R. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005380.pub4 · Cited by 37
Drug-like chelating agents: a potential lead for Alzheimer's disease
Huang, W., Wei, W., & Shen, Z. (2014) · RSC Advances · doi:10.1039/c4ra09193k · Cited by 33
Rodríguez‐Rodríguez, C., Telpoukhovskaia, M. A., Alí‐Torres, J., Rodríguez-Santiago, L., Manso, Y., Bailey, G. A., Hidalgo, J., Sodupe, M., & Orvig, C. (2015) · Metallomics · doi:10.1039/c4mt00167b · Cited by 29
Rehema, A. (2004) · DSpace repository (University of Tartu) · Cited by 29
Trace element alterations in Alzheimer's disease: A review
Cilliers, K. (2021) · Clinical Anatomy · doi:10.1002/ca.23727 · Cited by 30
“has been specifically used in iron overload (Bush, 2008; Regland et al., 2001).”
BackgroundMethodInfluentialSummers, K. L., Roseman, G. P., Schilling, K. M., Dolgova, N. V., Pushie, M. J., Sokaras, D., Kröll, T., Harris, H. H., Millhauser, G. L., Pickering, I. J., et al. (2022) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.2c01694 · Cited by 30
Clioquinol Decreases Levels of Phosphorylated, Truncated, and Oligomerized Tau Protein
Lin, G., Zhu, F., Kanaan, N. M., Asano, R., Shirafuji, N., Sasaki, H., Yamaguchi, T., Enomoto, S., Endo, Y., Ueno, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112063 · Cited by 29
“In a clinical trial, vitamin B12 supplementation was started before CQ treatment for 3 weeks and no severe side effects were noted [26].”
BackgroundMethodWang, T., Zheng, W., Xu, H. J., Zhou, J., & Wang, Z. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011888 · Cited by 31
“In addition, preliminary data from clinical trials have shown that CQ has positive effects on AD patients [20,21,22].”
BackgroundLiu, Y., Song, X., Chen, Z., Gu, Y., Peng, Y., & Liang, H. (2011) · Inorganica Chimica Acta · doi:10.1016/j.ica.2011.10.002 · Cited by 26
Anodic behavior of clioquinol at a glassy carbon electrode
Ghalkhani, M., Fernandes, I. P. G., Oliveira, S. C. B., Shahrokhian, S., & Oliveira‐Brett, A. M. (2010) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2010.10.001 · Cited by 29
“CQ has been successfully used, in combination with vitamin B12, for the treatment of Alzheimer's disease [7–9].”
MethodKrawczyk, M., Pastuch-Gawołek, G., Pluta, A., Erfurt, K., Domiński, A., & Kurcok, P. (2019) · Molecules · doi:10.3390/molecules24224181 · Cited by 26
“Particularly, derivatives of 8-hydroxyquinoline (8-HQ) are successfully applied to design chemotherapeutics used in the treatment of bacterial [7–9], fungal [10,11] and neurodegenerative diseases [12,13].”
BackgroundKuchárová, V., Drweesh, E. A., Lüköová, A., Sabolová, D., Radojević, I. D., Čomić, L. R., Vasić, S., Paulíková, H., Fečko, S., Balašková, T., et al. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.11.021 · Cited by 23
Cuproptosis and copper as potential mechanisms and intervention targets in Alzheimer's disease
Li, Y., Han, Y., Shu, Q., Kan, Y.-K., & Wang, Z. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117814 · Cited by 26
Devi, R., Ganesan, M., Chen, T.-W., Chen, S.-M., Al-Hemaid, F., Ali, M. A., & Al-Mohaimeed, A. M. (2022) · Electrochimica Acta · doi:10.1016/j.electacta.2022.139930 · Cited by 20
Liu, G., Men, P., Perry, G. L., & Smith, M. A. (2009) · Progress in brain research · doi:10.1016/s0079-6123(08)80005-2 · Cited by 26
“1), such as desferrioxamine (DFO), ethylenediaminetetraacetic acid (EDTA), and iodochlorhydroxyquin (clioquinol), have been used to treat patients with AD and provided significant clinical improvement (Casdorph, 2001; Crapper McLachlan et al., 1991; Regland et al., 2001; Ritchie et al., 2003).”
BackgroundEl‐Megharbel, S. M., & Refat, M. S. E.-D. (2015) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2014.12.081 · Cited by 23
Devi, R., Ganesan, M., Chen, T.-W., Chen, S. H. A., Akilarasan, M., Rwei, S., Yu, J., Lin, K.-Y., & Shaju, A. (2023) · Chemical engineering research & design · doi:10.1016/j.psep.2023.02.049 · Cited by 18
DNA repair deficiencies and neurodegeneration
Ropert, B., Gallrein, C., & Schumacher, B. (2024) · DNA repair · doi:10.1016/j.dnarep.2024.103679 · Cited by 24
Martínez, A., Alcendor, R. R., Rahman, T., Magdalena, P., Ismaila, S., & McCurdy, R. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.06.012 · Cited by 21
Vranec, P., Potočňák, I., & Kavečanský, V. (2012) · Polyhedron · doi:10.1016/j.poly.2012.03.046 · Cited by 20
Behbehani, G. R., & Mirzaie, M. (2009) · Journal of Thermal Analysis and Calorimetry · doi:10.1007/s10973-008-9311-9 · Cited by 20
Anti-Copper Therapies in Alzheimers Disease: New Concepts
Squitti, R., & Zito, G. (2009) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488909789104802 · Cited by 21
A generic class of amyloid fibril inhibitors
Ow, S., Bekard, I. B., Blencowe, A., Qiao, G. G., & Dunstan, D. E. (2014) · Journal of Materials Chemistry B · doi:10.1039/c4tb01762e · Cited by 20
Kharadi, G. J. (2013) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2013.09.049 · Cited by 19
Synthesis and Cytoprotective Characterization of 8-Hydroxyquinoline Betti Products
Kanizsai, I., Madácsi, R., Hackler, L., Gyuris, M., Szebeni, G. J., Huzián, O., & Puskás, L. G. (2018) · Molecules · doi:10.3390/molecules23081934 · Cited by 21
Martínez, A., Zahran, M., Gomez, M., Cooper, C., Guevara, J., Ekengard, E., Nordlander, E., Alcendor, R. R., & Hambleton, S. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.08.019 · Cited by 19
The case for iron chelation and/or antioxidant therapy in Alzheimer's disease
Malecki, E. A., & Connor, J. R. (2002) · Drug Development Research · doi:10.1002/ddr.10105 · Cited by 18
“The compound clioquinol is being tested with some initial success in AD [Regland et al., 2001].”
BackgroundNovel Quinoline-based Ir(III) Complexes Exhibit High Antitumor Activity in Vitro and in Vivo
Yang, Y., Bin, Y.-D., Qin, Q., Luo, X.-J., Zou, B., & Zhang, H. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00337 · Cited by 19
Patel, K. S., Patel, J. C., Dholariya, H. R., & Patel, K. D. (2012) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2012.05.057 · Cited by 18
Kawada, H., Blessing, K., Kiyota, T., Woolman, T. A., Winchester, L. C., & Kador, P. F. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-132471 · Cited by 18
“Most of these drugs have failed to show in vivo efficacy; however, orally administered clioquinol (PBT1) has demonstrated the ability to not only decrease A levels by nearly 50% without severe toxic effects but also to improve cognition in animal studies [11, 12] and pilot clinical studies [13, 14].”
Ismail, T., Mauerhofer, E., & Slomianka, L. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.09.011 · Cited by 16
Feasibility of Repurposing Clioquinol for Cancer Therapy
Khan, R., Khan, H. J., Abdullah, Y., & Dou, Q. P. (2020) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892815666200227090259 · Cited by 15
(2006) · Wiley eBooks · doi:10.1002/9780470041000.cedt079 · Cited by 15
A Preliminary Study of Cu Exposure Effects upon Alzheimer’s Amyloid Pathology
Pilozzi, A. R., Yu, Z., Carreras, I., Cormier, K., Hartley, D. M., Rogers, J. T., Dedeoglu, A., & Huang, X. (2020) · Biomolecules · doi:10.3390/biom10030408 · Cited by 14
“The metal-complexing agent clioquinol (CQ) appeared to improve cognitive health in MCI and AD patients [47,48], though further studies of the drug were discontinued, and evidence to support its efficacy and safety is lacking [49].”
BackgroundEvidence for presence of Zn+2-binding site in acetylcholinesterase
Rajesh, R. V., Balasubramanian, A. S., & Boopathy, R. (2009) · Biochimie · doi:10.1016/j.biochi.2009.01.001 · Cited by 16
Endogenous Zinc in Neurological Diseases
Koh, J.-Y. (2005) · Journal of Clinical Neurology · doi:10.3988/jcn.2005.1.2.121 · Cited by 13
RetractedKuchárová, V., Kuchár, J., Lüköová, A., Jendželovský, R., Majerník, M., Fedoročko, P., Vilková, M., Radojević, I. D., Čomić, L. R., & Potočňák, I. (2019) · Polyhedron · doi:10.1016/j.poly.2019.05.064 · Cited by 10
Memory restorative ability of clioquinol in copper–cholesterol-induced experimental dementia in mice
Mehra, R., Sodhi, R. K., & Aggarwal, N. (2015) · Pharmaceutical Biology · doi:10.3109/13880209.2014.974061 · Cited by 13
“Chronic exposure to excess copper ions selectively dysregulates CDK5, one of the major kinases associated with abnormal tau phosphorylation in the brain (Regland et al., 2001).”
BackgroundPharmacology of Alzheimer’s Disease: Appraisal and Prospects
Sellal, F., Nieoullon, A. L., Michel, G., Michel, B. F., Lacomblez, L., Geerts, H., Stula, A. D., Bordet, R., Bentué‐Ferrer, D., & Allain, H. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000084400 · Cited by 19
“reported that, in vitro, copper and zinc are two elements that promote aggregation related to the formation of senile plaques. In view of the increased cerebral concentrations of these two metals with age, it appears logical that limitation of copper and zinc concentrations in the brain could help to limit the formati…”
ResultLee, J., Park, J., Choi, J., Kang, S., Kang, Y., & Park, K. H. (2017) · Journal of Fish Diseases · doi:10.1111/jfd.12741 · Cited by 11
Ruthenium(II)–arene complexes with chelating quinoline ligands as anti-amyloid agents
Meiss, C. J., Bothwell, P. J., & Webb, M. I. (2021) · Canadian Journal of Chemistry · doi:10.1139/cjc-2021-0180 · Cited by 10
Gu, Y. J., Tang, T., Qiu, M., Wang, H., Ampofo, E., Menger, M. D., & Laschke, M. W. (2025) · Angiogenesis · doi:10.1007/s10456-024-09965-1 · Cited by 11
“Despite its historical association with SMON, clioquinol showed no toxicity in clinical trials for Alzheimer’s disease [39, 40].”
Regulation of Neuroactive Metals by the Choroid Plexus
Li, G. J., & Zheng, W. (2005) · CRC Press eBooks · doi:10.1201/9781420023404.ch9 · Cited by 9
“The levels of CSF-Tau protein also correlate significantly with the serum levels of Cu in Alzheimer’s disease patients treated with clioquinol; the latter is a chelator that crosses the blood–brain barrier and has greater affinity for Zn and Cu ions than for Ca and Mg ions (Regland et al., 2001).”
BackgroundA novel method for thermodynamic study on binding of copper ion with Alzheimer’s amyliod β peptide
Behbehani, R. G. (2009) · 中国科学通报:英文版 · doi:10.1007/s11434-009-0065-y · Cited by 7
β‐Amyloid Therapeutic Strategies for Alzheimer's Disease
Imbimbo, B. P., & Speroni, F. (2005) · Wiley eBooks · doi:10.1002/0471266949.bmc112 · Cited by 6
Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease
Mir, R. H., Masoodi, M. H., Shah, A. J., Mohi-ud-din, R., Sabreen, S., Wani, T. U., Jan, R., Javed, M. N., & Mir, P. A. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220903095837 · Cited by 6
Schmitt, S. M., Deshmukh, R. R., & Dou, Q. P. (2014) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-06752-0_1 · Cited by 8
Folarin, O. R., Olopade, F. E., & Olopade, J. O. (2021) · Nigerian Journal of Physiological Sciences · doi:10.54548/njps.v36i2.1 · Cited by 6
Pharmacologie de la maladie d’Alzheimer : vision du futur
Sellal, F., Nieoullon, A. L., Michel, G., Michel, B., Lacomblez, L., Geerts, H., Delini‐Stula, A., Bentué‐Ferrer, D., Bordet, R., & Allain, H. (2005) · Therapies · doi:10.2515/therapie:2005013 · Cited by 5
Copper in Brain and Neurodegeneration
Liddell, J. R., Bush, A. I., & White, A. R. (2004) · Wiley eBooks · doi:10.1002/9781119951438.eibc2143 · Cited by 6
Liu, Y., Ren, H., Wu, C., Bai, S., Zhang, X.-K., & Ru, B. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.12.087 · Cited by 5
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.
Wang, W. T., Tailor, B. A., Cohen, D. S., & Huang, X. (2019) · PubMed · Cited by 7
Drug repurposing and nanoparticles: New strategies against leishmaniasis
Casadei, B. R., Lotierzo, M. C. G., Malheiros, B., & Barbosa, L. R. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821100-7.00007-8 · Cited by 6
ALZHEIMER’S DISEASE THERAPEUTIC APPROACHES
Sandhya, A., & Gomathi, K. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i7.25104 · Cited by 4
Liu, G., Men, P., Perry, G. L., & Smith, M. A. (2003) · Wiley eBooks · doi:10.1002/9783527610419.ntls0122 · Cited by 3
Liu, G., Men, P., Zhu, X., & Perry, G. L. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.32 · Cited by 4
Targeting non-apoptotic regulated cell death (RCD) to treat neurodegenerative diseases
Zhao, W., Lai, Y., Li, Z., Yuan, Z., Wen, Z., & Zhang, L. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.040 · Cited by 3
CNT PLATFORMS BIOCOMPATIBILITY AND IMPACT ON NEURONAL PERFORMANCE
(2012) · CRC Press eBooks · doi:10.1201/b11835-21 · Cited by 1
Understanding and Treating Alzheimer’s Disease
Kumar, U., Roland, A., & Burbidge, S. A. (2007) · Springer eBooks · doi:10.1007/1-4020-5058-5_4 · Cited by 3
“Clinical assessment showed slight improvement after 3 weeks treatment with clioquinol in this open study (Regland et al., 2001).”
MethodIron and Copper in Alzheimer’s Disease
Loef, M., & Walach, H. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407824-6.00052-5 · Cited by 2
Deshpande, R. (2022) · Medicinal & Analytical Chemistry International · doi:10.23880/macij-16000174 · Cited by 2
Metal Complexing Agents for the Treatment of Alzheimer's Disease
White, A. R., & Bush, A. I. (2007) · Springer eBooks · doi:10.1007/7355_2007_011 · Cited by 2
Perspectives of Alzheimer's disease treatments
Davis, J. B., Bountra, C., & Richardson, J. C. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01226-2 · Cited by 3
Nutrients and Drugs in Alzheimer’s Disease: Harnessing Antioxidants
Shteinberg, M., Nissim, T., Zaken, K. B., Sawaid, I. O., Segev, L., Mesfin, S., Frankel, P., Ezzy, R., Saha, T., Bloch, N., et al. (2025) · International journal of Nutrition Pharmacology Neurological Diseases · doi:10.4103/ijnpnd.ijnpnd_123_25 · Cited by 1
Doddanagowada, S., & Palakollu, V. N. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.118633 · Cited by 1
Metadata
- Authors
- Regland, B., Lehmann, W., Abedini, I., Blennow, K., Jonsson, M., Karlsson, I., Sjögren, M., Wallin, A., Xilinas, M., & Gottfries, C.-G.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2001
- Volume
- 12
- Issue
- 6
- Pages
- 408-414
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W2079722596
- Cited by
- 220
- References
- 30
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 8 · 2020: 8 · 2019: 5 · 2018: 6 · 2017: 8 · 2016: 4 · 2015: 10 · 2014: 9 · 2013: 4 · 2012: 20
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Dementia and Geriatric Cognitive Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
- Keywords
- Alzheimer's disease, clioquinol, metal chelation, zinc, copper, blood-brain barrier, amyloid plaques, cerebrospinal fluid, tau protein, GAP-43, serum copper, copper/zinc ratio, clinical improvement
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Chelating Agents, Copper, Dose-Response Relationship, Drug, Female, Humans, Clioquinol, Male, Middle Aged, Zinc, Chelation Therapy, tau Proteins, Treatment Outcome, GAP-43 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.